ArticleAdvanced healthcare materials2025
Differential Phase Contrast Imaging to Predict MSC Immune Function.
Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Sphingolipid Metabolism Links Morphological Signatures to Immunomodulatory Potency in Human Mesenchymal Stromal Cells.Cellular and molecular bioengineering · 2026Article
- Current trends in electrospun nanofibers combined with mesenchymal stem cells for diabetic foot ulcer repair and regenerative therapy.iScience · 2026Review
- Deep learning-based in silico labeling for analyzing morphological features of MSCs to predict immunomodulatory capacity.Communications biology · 2026Article
- Differential Phase Contrast Imaging to Predict MSC Immune Function.Advanced healthcare materials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Mesenchymal stromal cells (MSCs) exhibit significant immunomodulatory potential, making them promising candidates for cell-based therapies in autoimmune and inflammatory diseases. However, the heterogeneity of MSC cultures and a lack of robust, predictive potency assays have hindered their clinical translation. In this study, the potential of single-cell morphological imaging during MSC expansion is explored as a method to estimate indoleamine-2,3-dioxygenase (IDO) protein and enzyme activity, a common immunosuppressive capacity measure. Fluorescence and label-free quantitative differential phase contrast (qDPC) imaging is employed to non-invasively extract morphological features from live MSCs during biomanufacturing with machine learning (ML) regression models to predict single cell IDO activity. qDPC imaging characterization is extended to estimate a previously established consensus model of MSC potency based on their IDO activity and immune suppression on T cells. These findings establish a foundation for scalable, non-destructive monitoring of MSC immunomodulatory capacity, facilitating the future development of quality control strategies for MSC manufacturing and clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.